Post-marketing Study of Monteplase ("Cleactor") in Patients With Acute Pulmonary Embolism
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00442234 |
Recruitment Status :
Completed
First Posted : March 1, 2007
Last Update Posted : October 18, 2018
|
Tracking Information | ||||
---|---|---|---|---|
First Submitted Date ICMJE | February 27, 2007 | |||
First Posted Date ICMJE | March 1, 2007 | |||
Last Update Posted Date | October 18, 2018 | |||
Actual Study Start Date ICMJE | May 1, 2007 | |||
Actual Primary Completion Date | April 1, 2008 (Final data collection date for primary outcome measure) | |||
Current Primary Outcome Measures ICMJE |
Monteplase antigen levels in plasma; Monteplase activity in plasma; parameters of coagulating and fibrinolytic system (Plasminogen activity, a2-PI, PIC, fibrinogen, D-dimer). | |||
Original Primary Outcome Measures ICMJE | Same as current | |||
Change History | ||||
Current Secondary Outcome Measures ICMJE |
Symptoms and signs of acute pulmonary embolism; pulmonary thrombosis; echocardiography; pulmonary arterial pressure; blood gas; vital signs; laboratory tests (e.g., hematology and blood chemistry); adverse events; concomitant therapies; dosing regimen. | |||
Original Secondary Outcome Measures ICMJE | Same as current | |||
Current Other Pre-specified Outcome Measures | Not Provided | |||
Original Other Pre-specified Outcome Measures | Not Provided | |||
Descriptive Information | ||||
Brief Title ICMJE | Post-marketing Study of Monteplase ("Cleactor") in Patients With Acute Pulmonary Embolism | |||
Official Title ICMJE | Pharmacokinetic/Pharmacodynamic Study of Monteplase ("Cleactor") in Acute Pulmonary Embolism | |||
Brief Summary | To investigate PK and coagulating and fibrinolytic parameter profiles (PD) at the approved dose (13,750 - 27,500 IU/kg) in patients with acute pulmonary embolism accompanying hemodynamic instability. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 4 | |||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
|||
Condition ICMJE | Pulmonary Embolism | |||
Intervention ICMJE | Drug: Monteplase | |||
Study Arms ICMJE | Not Provided | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE |
5 | |||
Original Enrollment ICMJE |
4 | |||
Actual Study Completion Date ICMJE | April 1, 2008 | |||
Actual Primary Completion Date | April 1, 2008 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria: 1) Patients who consent for study participation and submit written informed consent with free will by patient or legally authorized representative. 2) Patients aged between 20 years or above and under 75 years old at the time of obtaining informed consent. 3) Patients with acute pulmonary embolism within 5 days after the onset. 4) Patients with acute pulmonary embolism with hemodynamic instability and fulfill all of the following 4 items:
Exclusion Criteria:
|
|||
Sex/Gender ICMJE |
|
|||
Ages ICMJE | 20 Years to 75 Years (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Japan | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00442234 | |||
Other Study ID Numbers ICMJE | E6010-J081-591 | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Current Responsible Party | Eisai Inc. | |||
Original Responsible Party | Not Provided | |||
Current Study Sponsor ICMJE | Eisai Inc. | |||
Original Study Sponsor ICMJE | Eisai Limited | |||
Collaborators ICMJE | Eisai Co., Ltd. | |||
Investigators ICMJE |
|
|||
PRS Account | Eisai Inc. | |||
Verification Date | January 2010 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |